Department of Defense (DOD) Fiscal Year 2005 (FY05) Chronic Myelogenous Leukemia Research Program (CMLRP) Therapeutic Development Award (TDA)

The summary for the Department of Defense (DOD) Fiscal Year 2005 (FY05) Chronic Myelogenous Leukemia Research Program (CMLRP) Therapeutic Development Award (TDA) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

Department of Defense (DOD) Fiscal Year 2005 (FY05) Chronic Myelogenous Leukemia Research Program (CMLRP) Therapeutic Development Award (TDA): The United States Army Medical Research and Materiel Command (USAMRMC), Office of the Congressionally Directed Medical Research Programs (CDMRP) invites applications for funding for the FY05 Chronic Myelogenous Leukemia Research Program (CMLRP) Therapeutic Development Award (TDA). The intent of the Therapeutic Development Award is to sponsor the preclinical assessment of therapeutics for Chronic Myelogenous Leukemia (CML). The CMLRP specifically seeks proposals in the following areas of preclinical drug development: identification of lead agents through screening of small molecule libraries; evaluation of novel and/or existing therapeutic modalities in preclinical model systems; design and implementation of pilot Good Manufacturing Practice (GMP) production of therapeutics; testing of pharmacological agents through advanced preclinical toxicology; and/or development of Investigational New Drug (IND) materials. The formation of multidisciplinary, multi-institutional consortia focused on a synergistic preclinical development project is strongly encouraged. Although there are no total dollar amount restrictions to these awards, programmatic priority will be given to smaller-scale, cost-efficient projects with well-defined endpoints. Funding can be requested for up to 3 years. Direct costs can cover salary, expenses including research supplies, and travel to scientific/technical meetings. The amount for this travel may not exceed $1,800 per year per investigator. Institutional support and commitment to foster the applicants research career, such as the provision of access to adequate laboratory facilities and equipment must be evident. If a biotechnology or pharmaceutical company applies for this mechanism as an individual submitter or as a part of a consortium, the company is expected to leverage its own resources to complement the funding provided for the study by this award. For proposals involving a consortium, direct costs also can cover expenses for meetings that bring together members of the consortium. The nature of this Program does not allow for renewal of grants or supplementation of existing grants. Approximately $2.2M is available for this award mechanism. Depending on the number and quality of the applications it is anticipated that approximately one to three proposals will be funded. The CMLRP Integration Panel reserves the right to partially fund any proposal. Electronic submission is required. Proposals will be accepted only as PDF files submitted through the CDMRP eReceipt system. No paper copy submissions will be accepted. The CDMRP uses a two-tier review process for proposals: scientific peer review, followed by programmatic review. Details of both tiers of review can be found in the Full Text of Program Announcement. Estimated timelines for the FY05 Clinical Trial Award proposals are as follows: Expected Letter of Intent: May 17, 2005; Full Proposal Submission Deadline: June 7, 2005, 5:00 p.m. Eastern Time; Peer Review: July, 2005; Programmatic Review: September, 2005; Award Start Date: Between October, 2005 and September, 2006. For additional information or questions, please contact: Patricia A. Evans, Contracting/Grants Office, U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, phone: (301) 619-7354, Fax: (301) 619-6662, email: [email protected]